In the following video, Motley Fool health care bureau chief Brenton Flynn discusses the lack of a pathway in the United States for approving drugs that are being called "biosimilars," in that they are similar to biological large-molecule drugs like how generic pharmaceuticals currently are similar to small-molecule drugs. Brenton discusses why this has remained such an untapped market in the U.S. and what the difficulties are in producing these far more complex drugs in the form of a marketable generic. He also tells us which companies stand to benefit from legislation putting a pathway to approval for these drugs into place in the U.S., and why companies like AbbVie would benefit from such legislation being delayed.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking, and as an added bonus, you'll receive a full year of free analyst updates as significant news hits. Simply click here now to claim your copy today.
The article Are Biosimilar Delays News or Noise? originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.